When to Discontinue Sacubitril/Valsartan
Sacubitril/valsartan should rarely be permanently discontinued in heart failure patients, as discontinuation is associated with significantly increased mortality and clinical deterioration. 1, 2, 3
Absolute Indications for Immediate Discontinuation
Stop sacubitril/valsartan immediately and permanently if:
- Angioedema occurs - Do not re-administer under any circumstances. Provide appropriate therapy including subcutaneous epinephrine 1:1000 (0.3-0.5 mL) if laryngeal involvement 1
- Pregnancy is detected - Switch to alternative therapy unless the drug is considered lifesaving for the mother and no appropriate alternative exists 1
- Severe hypersensitivity reaction to either sacubitril or valsartan components 1
Temporary Discontinuation or Dose Reduction Scenarios
For symptomatic hypotension:
- First, adjust diuretics and other vasodilators (nitrates, calcium channel blockers) 1
- Correct volume depletion if present
- If hypotension persists despite these measures, reduce the dose by 50% rather than discontinuing 1
- Permanent discontinuation is usually not required 1
For significant renal dysfunction:
- If serum creatinine doubles or eGFR drops significantly, down-titrate the dose rather than stop 1
- Monitor closely and adjust diuretics
- Consider temporary interruption only if acute kidney injury develops, with plan to restart when stable 4
For hyperkalemia:
- If potassium >5.5 mmol/L: reduce dose by 50% 5
- If potassium >6.0 mmol/L: temporarily stop and seek specialist advice, but plan to restart with potassium management 5
- Consider potassium binders (patiromer, zirconium cyclosilicate) to enable continuation 4
Critical Evidence on Discontinuation Outcomes
The evidence strongly argues against discontinuation. Patients who discontinued sacubitril/valsartan showed:
- 13-fold increased cardiovascular mortality (HR 13.22,95% CI 6.71-15.73) 3
- 13.5-fold increased all-cause mortality (HR 13.51,95% CI 3.22-56.13) 3
- Worsening NYHA class, declining LVEF, and increased end-diastolic volume even when switched back to ACE inhibitors or ARBs 2
Management Algorithm for Adverse Events
Instead of discontinuing, follow this sequence:
For hypotension (most common reason for discontinuation):
For worsening heart failure symptoms:
For renal dysfunction:
Special Populations Requiring Caution
Higher discontinuation risk in patients with:
- ATTR cardiac amyloidosis (76.5% discontinuation rate, primarily due to hypotension) 8
- Advanced NYHA Class IV heart failure (18% unable to tolerate even during run-in, 29% discontinued during trial) 9
- Baseline SBP <110 mmHg 7, 10
- Albumin <3.5 g/dL or BMI <18.5 kg/m² 11
These patients require more intensive monitoring but should still attempt therapy given the mortality benefit.
Key Pitfalls to Avoid
- Do not stop abruptly without attempting dose reduction first - permanent discontinuation is rarely necessary 1
- Do not discontinue for asymptomatic hypotension or mild creatinine elevation - these often stabilize with supportive measures 7
- Do not assume ACE inhibitors/ARBs are equivalent alternatives - switching back results in worse outcomes 2
- Do not delay restarting after temporary interruption - the longer the delay, the worse the outcomes 3